News | September 29, 2010

Implantable Cardiac Monitor Detects Asymptomatic Arrhythmias


September 29, 2010 – A prospective study found that an implantable cardiac monitor detected arrhythmias in patients who had suffered a heart attack.

The CARISMA study, which looked at Medtronic’s Reveal Plus monitor, found that it recorded arrhythmias in 46 percent of patients with ejection fractions less than or equal to 40 percent and who had previously suffered an acute myocardial infarction (AMI). Nearly 86 percent of the arrhythmias detected were asymptomatic.

The study is the first to investigate the incidence and prognostic significance of arrhythmias documented by an insertable cardiac monitor in this patient population. Results were published in Circulation.

“For the first time there are data showing that continuous long-term monitoring allows detailed insight into post-AMI arrhythmias,” said Poul Erik Bloch Thomsen, M.D., the principal investigator, Gentofte University Hospital, Copenhagen, Denmark. “Additional information about post-AMI patients can help physicians determine appropriate medical intervention, such as an implantable cardioverter-defibrillator, pacemaker, or modified drug therapy.”

Pinpointing the frequency of arrhythmias in post-AMI patients has been limited due to a lack of clinically validated measurement tools.

Of the patients diagnosed with cardiac arrhythmias, 27 percent experienced new onset atrial fibrillation, 9.8 percent had high-degree atrioventricular (AV) block, 6.7 percent had sinus bradycardia, and 13 percent had non-sustained ventricular tachycardia. Additionally, 56 patients received an implantable cardioverter-defibrillator (11 for secondary indications; 45 for primary indications) and 15 patients received a pacemaker.

For more information: www.medtronic.com


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now